S

Sangamo Therapeutics, Inc.

485 employees

Sangamo researches, develops and commercializes engineered DNA-binding proteins for the development of novel therapeutic strategies.

Basic info

Industry

biotechnology research

Sectors

Genome Editing
Biotechnology
MPS II
Beta Thalassemia
Gene Therapy
Fabry
Hemophilia B
Pharmaceutical
Cell Therapy
Hemophilia A
Tauopathies
Immunology
Health Care
Therapeutics
Genetics
MPS I

Date founded

1995

Funding rounds raised

Total raised

$11M

from 2 investors over 2 rounds

S

Sangamo Therapeutics, Inc. raised $11M on February 7, 2018

Investors: National Institutes of Health

S

Sangamo Therapeutics, Inc. raised undisclosed on December 24, 2013

Investors: Matthew Brown Companies

FAQ